Potential for elimination of SAR‐CoV‐2 through vaccination as inspired by elimination of multiple influenza viruses through natural pandemics or mass vaccination

The ongoing pandemic of coronavirus disease 2019 (COVID‐19) caused by the novel virus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has claimed many lives worldwide. To combat the pandemic, multiple types of vaccines are under development with unprecedented rapidity. Theoretically, fu...

Full description

Saved in:
Bibliographic Details
Published inJournal of medical virology Vol. 92; no. 11; pp. 2453 - 2457
Main Authors Chen, Ji‐Ming, Sun, Ying‐Xue, Chen, Ji‐Wang
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.11.2020
John Wiley and Sons Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The ongoing pandemic of coronavirus disease 2019 (COVID‐19) caused by the novel virus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has claimed many lives worldwide. To combat the pandemic, multiple types of vaccines are under development with unprecedented rapidity. Theoretically, future vaccination against COVID‐19 may fall into long‐term costly guerrilla warfare between SARS‐CoV‐2 and humans. Elimination of SARS‐CoV‐2 through vaccination to avoid the potential long‐term costly guerrilla warfare, if possible, is highly desired and worth intensive consideration. Human influenza pandemics emerging in 1957, 1968, and 2009 established strong global herd immunity and led to the elimination of three human influenza viruses, which circulated worldwide for years before the pandemics. Moreover, both clade 7.2 of subtype H5 highly pathogenic avian influenza virus and subtype H7N9 avian influenza virus circulated in poultry in China for years, and they have been virtually eliminated through mass vaccination in recent years. These facts suggest that the rapid establishment of global herd immunity through mass vaccination using an appropriate vaccine could eliminate SARS‐CoV‐2. The coming 2 years are a golden time for elimination through vaccination, which requires tremendous national and international collaboration. This review also prioritizes the efficacy of vaccines for COVID‐19 and elucidates the importance of the development of more live vaccines for COVID‐19. Highlights Future vaccination against coronavirus disease 2019 (COVID‐19) may fall into long‐term costly guerrilla warfare between severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and humans. Elimination of SARS‐CoV‐2 through vaccination is highly desired and worth intensive consideration. Multiple influenza viruses have been eliminated through natural pandemics or mass vaccination. The coming 2 years are a golden time for the elimination of SARS‐CoV‐2 through mass vaccination. Rapid establishment of global herd immunity through vaccination using a live vaccine could eliminate SARS‐CoV‐2.
AbstractList The ongoing pandemic of coronavirus disease 2019 (COVID‐19) caused by the novel virus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has claimed many lives worldwide. To combat the pandemic, multiple types of vaccines are under development with unprecedented rapidity. Theoretically, future vaccination against COVID‐19 may fall into long‐term costly guerrilla warfare between SARS‐CoV‐2 and humans. Elimination of SARS‐CoV‐2 through vaccination to avoid the potential long‐term costly guerrilla warfare, if possible, is highly desired and worth intensive consideration. Human influenza pandemics emerging in 1957, 1968, and 2009 established strong global herd immunity and led to the elimination of three human influenza viruses, which circulated worldwide for years before the pandemics. Moreover, both clade 7.2 of subtype H5 highly pathogenic avian influenza virus and subtype H7N9 avian influenza virus circulated in poultry in China for years, and they have been virtually eliminated through mass vaccination in recent years. These facts suggest that the rapid establishment of global herd immunity through mass vaccination using an appropriate vaccine could eliminate SARS‐CoV‐2. The coming 2 years are a golden time for elimination through vaccination, which requires tremendous national and international collaboration. This review also prioritizes the efficacy of vaccines for COVID‐19 and elucidates the importance of the development of more live vaccines for COVID‐19. Future vaccination against coronavirus disease 2019 (COVID‐19) may fall into long‐term costly guerrilla warfare between severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and humans. Elimination of SARS‐CoV‐2 through vaccination is highly desired and worth intensive consideration. Multiple influenza viruses have been eliminated through natural pandemics or mass vaccination. The coming 2 years are a golden time for the elimination of SARS‐CoV‐2 through mass vaccination. Rapid establishment of global herd immunity through vaccination using a live vaccine could eliminate SARS‐CoV‐2.
The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the novel virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has claimed many lives worldwide. To combat the pandemic, multiple types of vaccines are under development with unprecedented rapidity. Theoretically, future vaccination against COVID-19 may fall into long-term costly guerrilla warfare between SARS-CoV-2 and humans. Elimination of SARS-CoV-2 through vaccination to avoid the potential long-term costly guerrilla warfare, if possible, is highly desired and worth intensive consideration. Human influenza pandemics emerging in 1957, 1968, and 2009 established strong global herd immunity and led to the elimination of three human influenza viruses, which circulated worldwide for years before the pandemics. Moreover, both clade 7.2 of subtype H5 highly pathogenic avian influenza virus and subtype H7N9 avian influenza virus circulated in poultry in China for years, and they have been virtually eliminated through mass vaccination in recent years. These facts suggest that the rapid establishment of global herd immunity through mass vaccination using an appropriate vaccine could eliminate SARS-CoV-2. The coming 2 years are a golden time for elimination through vaccination, which requires tremendous national and international collaboration. This review also prioritizes the efficacy of vaccines for COVID-19 and elucidates the importance of the development of more live vaccines for COVID-19.The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the novel virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has claimed many lives worldwide. To combat the pandemic, multiple types of vaccines are under development with unprecedented rapidity. Theoretically, future vaccination against COVID-19 may fall into long-term costly guerrilla warfare between SARS-CoV-2 and humans. Elimination of SARS-CoV-2 through vaccination to avoid the potential long-term costly guerrilla warfare, if possible, is highly desired and worth intensive consideration. Human influenza pandemics emerging in 1957, 1968, and 2009 established strong global herd immunity and led to the elimination of three human influenza viruses, which circulated worldwide for years before the pandemics. Moreover, both clade 7.2 of subtype H5 highly pathogenic avian influenza virus and subtype H7N9 avian influenza virus circulated in poultry in China for years, and they have been virtually eliminated through mass vaccination in recent years. These facts suggest that the rapid establishment of global herd immunity through mass vaccination using an appropriate vaccine could eliminate SARS-CoV-2. The coming 2 years are a golden time for elimination through vaccination, which requires tremendous national and international collaboration. This review also prioritizes the efficacy of vaccines for COVID-19 and elucidates the importance of the development of more live vaccines for COVID-19.
The ongoing pandemic of coronavirus disease 2019 (COVID‐19) caused by the novel virus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has claimed many lives worldwide. To combat the pandemic, multiple types of vaccines are under development with unprecedented rapidity. Theoretically, future vaccination against COVID‐19 may fall into long‐term costly guerrilla warfare between SARS‐CoV‐2 and humans. Elimination of SARS‐CoV‐2 through vaccination to avoid the potential long‐term costly guerrilla warfare, if possible, is highly desired and worth intensive consideration. Human influenza pandemics emerging in 1957, 1968, and 2009 established strong global herd immunity and led to the elimination of three human influenza viruses, which circulated worldwide for years before the pandemics. Moreover, both clade 7.2 of subtype H5 highly pathogenic avian influenza virus and subtype H7N9 avian influenza virus circulated in poultry in China for years, and they have been virtually eliminated through mass vaccination in recent years. These facts suggest that the rapid establishment of global herd immunity through mass vaccination using an appropriate vaccine could eliminate SARS‐CoV‐2. The coming 2 years are a golden time for elimination through vaccination, which requires tremendous national and international collaboration. This review also prioritizes the efficacy of vaccines for COVID‐19 and elucidates the importance of the development of more live vaccines for COVID‐19. Highlights Future vaccination against coronavirus disease 2019 (COVID‐19) may fall into long‐term costly guerrilla warfare between severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and humans. Elimination of SARS‐CoV‐2 through vaccination is highly desired and worth intensive consideration. Multiple influenza viruses have been eliminated through natural pandemics or mass vaccination. The coming 2 years are a golden time for the elimination of SARS‐CoV‐2 through mass vaccination. Rapid establishment of global herd immunity through vaccination using a live vaccine could eliminate SARS‐CoV‐2.
The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the novel virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has claimed many lives worldwide. To combat the pandemic, multiple types of vaccines are under development with unprecedented rapidity. Theoretically, future vaccination against COVID-19 may fall into long-term costly guerrilla warfare between SARS-CoV-2 and humans. Elimination of SARS-CoV-2 through vaccination to avoid the potential long-term costly guerrilla warfare, if possible, is highly desired and worth intensive consideration. Human influenza pandemics emerging in 1957, 1968, and 2009 established strong global herd immunity and led to the elimination of three human influenza viruses, which circulated worldwide for years before the pandemics. Moreover, both clade 7.2 of subtype H5 highly pathogenic avian influenza virus and subtype H7N9 avian influenza virus circulated in poultry in China for years, and they have been virtually eliminated through mass vaccination in recent years. These facts suggest that the rapid establishment of global herd immunity through mass vaccination using an appropriate vaccine could eliminate SARS-CoV-2. The coming 2 years are a golden time for elimination through vaccination, which requires tremendous national and international collaboration. This review also prioritizes the efficacy of vaccines for COVID-19 and elucidates the importance of the development of more live vaccines for COVID-19.
The ongoing pandemic of coronavirus disease 2019 (COVID‐19) caused by the novel virus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has claimed many lives worldwide. To combat the pandemic, multiple types of vaccines are under development with unprecedented rapidity. Theoretically, future vaccination against COVID‐19 may fall into long‐term costly guerrilla warfare between SARS‐CoV‐2 and humans. Elimination of SARS‐CoV‐2 through vaccination to avoid the potential long‐term costly guerrilla warfare, if possible, is highly desired and worth intensive consideration. Human influenza pandemics emerging in 1957, 1968, and 2009 established strong global herd immunity and led to the elimination of three human influenza viruses, which circulated worldwide for years before the pandemics. Moreover, both clade 7.2 of subtype H5 highly pathogenic avian influenza virus and subtype H7N9 avian influenza virus circulated in poultry in China for years, and they have been virtually eliminated through mass vaccination in recent years. These facts suggest that the rapid establishment of global herd immunity through mass vaccination using an appropriate vaccine could eliminate SARS‐CoV‐2. The coming 2 years are a golden time for elimination through vaccination, which requires tremendous national and international collaboration. This review also prioritizes the efficacy of vaccines for COVID‐19 and elucidates the importance of the development of more live vaccines for COVID‐19.
Author Sun, Ying‐Xue
Chen, Ji‐Wang
Chen, Ji‐Ming
AuthorAffiliation 1 College of Veterinary Medicine Qingdao Agricultural University Qingdao China
3 Department of Medicine University of Illinois at Chicago Chicago Illinois
2 Qingdao Six‐Eight Nearby Sci‐Tech Company Qingdao China
AuthorAffiliation_xml – name: 1 College of Veterinary Medicine Qingdao Agricultural University Qingdao China
– name: 2 Qingdao Six‐Eight Nearby Sci‐Tech Company Qingdao China
– name: 3 Department of Medicine University of Illinois at Chicago Chicago Illinois
Author_xml – sequence: 1
  givenname: Ji‐Ming
  orcidid: 0000-0002-0404-0830
  surname: Chen
  fullname: Chen, Ji‐Ming
  email: jmchen678@qq.com
  organization: Qingdao Six‐Eight Nearby Sci‐Tech Company
– sequence: 2
  givenname: Ying‐Xue
  surname: Sun
  fullname: Sun, Ying‐Xue
  organization: Qingdao Six‐Eight Nearby Sci‐Tech Company
– sequence: 3
  givenname: Ji‐Wang
  surname: Chen
  fullname: Chen, Ji‐Wang
  organization: University of Illinois at Chicago
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32525587$$D View this record in MEDLINE/PubMed
BookMark eNp1kktuFDEQhi0URCaBBRdAltjAohM_-7FBikY8FQTika3ltt0Zj9x2x-4eNKw4ApfgYpwEJzMThRFsbKnqq79-l-sIHPjgDQCPMTrBCJHTZb86ISUuyT0ww6gpiwZV-ADMEGZlUZaYH4KjlJYIoboh5AE4pIQTzutqBn59DKPxo5UOdiFC42xvvRxt8DB08PPZp98_fs7DRT4JHBcxTJcLuJJK7SCZoPVpsNFo2K736_vJjXZwJjOdm4z_LuHKximZdCuW4Snm7oP02vRWJZht9DKlu20egvuddMk82t7H4Ourl1_mb4rzD6_fzs_OC8VpRQrdMI0kq-paUsQb3nZU8pyiSvPrIGuZJjnMcadaTrCkhNGmamqtMdK0osfgxUZ3mNreaJUnk72JIdpexrUI0oq_M94uxGVYiYoiVFKUBZ5tBWK4mkwaRW-TMs5Jb8KUBGGYENRUZZ3Rp3voMkzR5-dlipVNzRmmmXpy19Gtld0PZuB0A6gYUoqmE8qON0PLBq0TGInrHRF5R8TNjuSK53sVO9F_sVv1b9aZ9f9B8e79xabiD5fc0NQ
CitedBy_id crossref_primary_10_4081_jphr_2022_2665
crossref_primary_10_1002_jmv_26453
crossref_primary_10_1177_22799036221107062
crossref_primary_10_1002_jmv_27661
crossref_primary_10_1002_jmv_26312
crossref_primary_10_1007_s11356_021_17055_8
crossref_primary_10_1002_jmv_27335
crossref_primary_10_1007_s00705_023_05815_5
Cites_doi 10.1371/journal.pone.0011184
10.1016/j.vaccine.2016.07.033
10.1016/S0140-6736(20)30566-3
10.1128/mBio.00150-11
10.1007/s11427-018-9420-1
10.1128/JVI.00855-16
10.1038/d41573-020-00073-5
10.1186/s12985-019-1188-7
10.1371/journal.pone.0232652
10.1016/j.rvsc.2020.04.009
10.3201/eid2012.140733
10.1371/journal.ppat.1005215
10.1038/d41586-020-01221-y
10.24272/j.issn.2095-8137.2019.045
ContentType Journal Article
Copyright 2020 Wiley Periodicals LLC
2020 Wiley Periodicals LLC.
Copyright_xml – notice: 2020 Wiley Periodicals LLC
– notice: 2020 Wiley Periodicals LLC.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7TK
7U9
8FD
C1K
FR3
H94
K9.
M7N
P64
RC3
7X8
5PM
DOI 10.1002/jmv.26162
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Bacteriology Abstracts (Microbiology B)
Neurosciences Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Virology and AIDS Abstracts
Technology Research Database
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

CrossRef
MEDLINE
Genetics Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
DocumentTitleAlternate CHEN et al
EISSN 1096-9071
EndPage 2457
ExternalDocumentID PMC7300630
32525587
10_1002_jmv_26162
JMV26162
Genre reviewArticle
Journal Article
Review
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
3O-
3SF
3WU
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AI.
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
ECGQY
EJD
ELTNK
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M65
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RGB
RIWAO
RJQFR
ROL
RWI
RX1
RYL
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
V2E
VH1
W8V
W99
WBKPD
WHG
WIB
WIH
WIJ
WIK
WJL
WNSPC
WOHZO
WQJ
WRC
WUP
WXI
WXSBR
WYISQ
X7M
XG1
XPP
XV2
ZGI
ZXP
ZZTAW
~IA
~KM
~WT
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7TK
7U9
8FD
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
C1K
FR3
H94
K9.
M7N
P64
RC3
7X8
5PM
ID FETCH-LOGICAL-c5372-d94d0a4788a30595bf3a5c533cd5788a4b4d295b51fcb521a32439798dd10d373
IEDL.DBID DR2
ISSN 0146-6615
1096-9071
IngestDate Thu Aug 21 14:34:10 EDT 2025
Fri Jul 11 08:03:23 EDT 2025
Sat Jul 26 02:17:21 EDT 2025
Wed Feb 19 02:29:08 EST 2025
Tue Jul 01 02:24:45 EDT 2025
Thu Apr 24 22:59:04 EDT 2025
Wed Jan 22 16:32:34 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords COVID-19
herd immunity
influenza
SARS-CoV-2
vaccine
pandemic
elimination
vaccination
Language English
License 2020 Wiley Periodicals LLC.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5372-d94d0a4788a30595bf3a5c533cd5788a4b4d295b51fcb521a32439798dd10d373
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-0404-0830
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC7300630
PMID 32525587
PQID 2446985413
PQPubID 105515
PageCount 5
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7300630
proquest_miscellaneous_2412209768
proquest_journals_2446985413
pubmed_primary_32525587
crossref_citationtrail_10_1002_jmv_26162
crossref_primary_10_1002_jmv_26162
wiley_primary_10_1002_jmv_26162_JMV26162
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate November 2020
PublicationDateYYYYMMDD 2020-11-01
PublicationDate_xml – month: 11
  year: 2020
  text: November 2020
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: London
– name: Hoboken
PublicationTitle Journal of medical virology
PublicationTitleAlternate J Med Virol
PublicationYear 2020
Publisher Wiley Subscription Services, Inc
John Wiley and Sons Inc
Publisher_xml – name: Wiley Subscription Services, Inc
– name: John Wiley and Sons Inc
References 2011; 2
1963; 88
2019; 40
2016; 90
2020; 580
2020; 131
2020
2020; 395
2015; 11
2019; 16
2020; 15
2018; 61
2003
2010; 5
2020; 19
2016; 34
2014; 20
e_1_2_9_22_1
e_1_2_9_10_1
e_1_2_9_13_1
Liu S (e_1_2_9_11_1) 2020
e_1_2_9_12_1
e_1_2_9_23_1
e_1_2_9_8_1
e_1_2_9_5_1
e_1_2_9_4_1
e_1_2_9_3_1
e_1_2_9_2_1
Bloom BR (e_1_2_9_16_1) 2003
Zhou X (e_1_2_9_7_1) 2020
Gao Q (e_1_2_9_6_1) 2020
e_1_2_9_9_1
e_1_2_9_15_1
e_1_2_9_14_1
e_1_2_9_17_1
e_1_2_9_19_1
e_1_2_9_18_1
Chen JW (e_1_2_9_21_1) 2020
Couch RB (e_1_2_9_20_1) 1963; 88
References_xml – volume: 90
  start-page: 9797
  issue: 21
  year: 2016
  end-page: 9805
  article-title: Characterization of clade 7.2 H5 avian influenza viruses that continue to circulate in chickens in China
  publication-title: J Virol
– volume: 580
  start-page: 576
  issue: 7805
  year: 2020
  end-page: 577
  article-title: The race for coronavirus vaccines: a graphical guide
  publication-title: Nature
– volume: 131
  start-page: 21
  year: 2020
  end-page: 23
  article-title: COVID‐19 from veterinary medicine and one health perspectives: what animal coronaviruses have taught us
  publication-title: Res Vet Sci
– volume: 16
  start-page: 85
  issue: 1
  year: 2019
  article-title: Diversity and distribution of type A influenza viruses: an updated panorama analysis based on protein sequences
  publication-title: Virol J
– volume: 61
  start-page: 1465
  issue: 12
  year: 2018
  end-page: 1473
  article-title: Vaccination of poultry successfully eliminated human infection with H7N9 virus in China
  publication-title: Sci China: Life Sci
– year: 2003
– volume: 395
  start-page: 1054
  issue: 10229
  year: 2020
  end-page: 1062
  article-title: Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study
  publication-title: Lancet
– start-page: 26
  year: 2020
  article-title: Follow‐up of asymptomatic patients with SARS‐CoV‐2 infection
  publication-title: Clin Microbiol Infect
– start-page: 92
  year: 2020
  article-title: Potential of live pathogen vaccines for defeating the COVID‐19 pandemic: history and mechanism
  publication-title: J Med Virol
– volume: 15
  issue: 5
  year: 2020
  article-title: Herd immunity and a vaccination game: an experimental study
  publication-title: PLOS One
– volume: 40
  start-page: 305
  issue: 4
  year: 2019
  end-page: 316
  article-title: Effect of temperature on antioxidant defense and innate immunity in Brandt's voles
  publication-title: Zool Res
– volume: 5
  issue: 6
  year: 2010
  article-title: The re‐emergence of H1N1 influenza virus in 1977: a cautionary tale for estimating divergence times using biologically unrealistic sampling dates
  publication-title: PLOS One
– volume: 19
  start-page: 305
  issue: 5
  year: 2020
  end-page: 306
  article-title: The COVID‐19 vaccine development landscape
  publication-title: Nat Rev Drug Discov
– volume: 11
  issue: 10
  year: 2015
  article-title: Identification of the mechanisms causing reversion to virulence in an attenuated SARS‐CoV for the design of a genetically stable vaccine
  publication-title: PLOS Pathog
– start-page: 67
  year: 2020
  article-title: Control of avian influenza in China: strategies and lessons
  publication-title: Transbound Emerg Dis
– start-page: 368
  year: 2020
  article-title: Rapid development of an inactivated vaccine candidate for SARS‐CoV‐2
  publication-title: Science
– volume: 2
  issue: 5
  year: 2011
  article-title: Why do influenza virus subtypes die out? A hypothesis
  publication-title: mBio
– volume: 88
  start-page: 394
  issue: Suppl
  year: 1963
  end-page: 403
  article-title: Immunization with types 4 and 7 adenovirus by selective infection of the intestinal tract
  publication-title: Am Rev Respir Dis
– volume: 34
  start-page: 4558
  issue: 38
  year: 2016
  end-page: 4564
  article-title: Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits
  publication-title: Vaccine
– volume: 20
  start-page: 2152
  issue: 12
  year: 2014
  end-page: 2154
  article-title: Subclinical highly pathogenic avian influenza virus infection among vaccinated chickens, China
  publication-title: Emerg Infect Dis
– ident: e_1_2_9_10_1
  doi: 10.1371/journal.pone.0011184
– ident: e_1_2_9_19_1
  doi: 10.1016/j.vaccine.2016.07.033
– ident: e_1_2_9_22_1
  doi: 10.1016/S0140-6736(20)30566-3
– ident: e_1_2_9_8_1
  doi: 10.1128/mBio.00150-11
– ident: e_1_2_9_14_1
  doi: 10.1007/s11427-018-9420-1
– start-page: 92
  year: 2020
  ident: e_1_2_9_21_1
  article-title: Potential of live pathogen vaccines for defeating the COVID‐19 pandemic: history and mechanism
  publication-title: J Med Virol
– ident: e_1_2_9_12_1
  doi: 10.1128/JVI.00855-16
– ident: e_1_2_9_17_1
– ident: e_1_2_9_2_1
  doi: 10.1038/d41573-020-00073-5
– ident: e_1_2_9_9_1
  doi: 10.1186/s12985-019-1188-7
– ident: e_1_2_9_15_1
  doi: 10.1371/journal.pone.0232652
– ident: e_1_2_9_4_1
  doi: 10.1016/j.rvsc.2020.04.009
– ident: e_1_2_9_13_1
  doi: 10.3201/eid2012.140733
– ident: e_1_2_9_18_1
– volume-title: The Vaccine Book
  year: 2003
  ident: e_1_2_9_16_1
– volume: 88
  start-page: 394
  year: 1963
  ident: e_1_2_9_20_1
  article-title: Immunization with types 4 and 7 adenovirus by selective infection of the intestinal tract
  publication-title: Am Rev Respir Dis
– ident: e_1_2_9_5_1
  doi: 10.1371/journal.ppat.1005215
– start-page: 368
  year: 2020
  ident: e_1_2_9_6_1
  article-title: Rapid development of an inactivated vaccine candidate for SARS‐CoV‐2
  publication-title: Science
– start-page: 67
  year: 2020
  ident: e_1_2_9_11_1
  article-title: Control of avian influenza in China: strategies and lessons
  publication-title: Transbound Emerg Dis
– ident: e_1_2_9_3_1
  doi: 10.1038/d41586-020-01221-y
– start-page: 26
  year: 2020
  ident: e_1_2_9_7_1
  article-title: Follow‐up of asymptomatic patients with SARS‐CoV‐2 infection
  publication-title: Clin Microbiol Infect
– ident: e_1_2_9_23_1
  doi: 10.24272/j.issn.2095-8137.2019.045
SSID ssj0008922
Score 2.3736928
SecondaryResourceType review_article
Snippet The ongoing pandemic of coronavirus disease 2019 (COVID‐19) caused by the novel virus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has claimed...
The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the novel virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has claimed...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2453
SubjectTerms Avian flu
Coronaviridae
Coronaviruses
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines - administration & dosage
COVID-19 Vaccines - immunology
elimination
Herd immunity
Humans
Immunity
Immunity, Herd
Influenza
International cooperation
Mass Vaccination - statistics & numerical data
Orthomyxoviridae
pandemic
Pandemics
Pandemics - prevention & control
Public health
Respiratory diseases
Review
Reviews
SARS‐CoV‐2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
vaccination
vaccine
Vaccines
Viral diseases
Virology
Viruses
Warfare
Title Potential for elimination of SAR‐CoV‐2 through vaccination as inspired by elimination of multiple influenza viruses through natural pandemics or mass vaccination
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjmv.26162
https://www.ncbi.nlm.nih.gov/pubmed/32525587
https://www.proquest.com/docview/2446985413
https://www.proquest.com/docview/2412209768
https://pubmed.ncbi.nlm.nih.gov/PMC7300630
Volume 92
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VPSAuUN6hBRnEgUu2iR3nIU5VRVVVWoQKrXpAivxadYFNqmZ3JXriJ_An-GP8EmacR7stSIhLFMWT2Elm7M-e8TcAr2QWWxmZOJQqxgmK0i4scBoRmlRwgeNb5PwOufG7dP8oOTiRJ2vwpt8L0_JDDAtuZBm-vyYDV7rZviQN_TxbjhD--_6XYrUIEB1eUkflRetBwJ4gxDFI9qxCEd8e7lwdi24AzJtxklfxqx-A9u7Cp77pbdzJl9Firkfm4hqr43--2wbc6YAp22k16R6sueo-3Bp3rvcH8PN9PafIIpRBnMuwAgqiod_K6gn7sHP46_uP3foYj5x1yX_YUhnTC6mGTSty6zvL9Lfr9_dxjSjjk6ZcKLacni8a1wwP8xSkWPsZLXvPpqZh2IwZYv-r1TyEo723H3f3wy7HQ2ikyHhoi8RGijj8FfY8hdQToSQWCWMlXUx0YjlelvHEaIQaCgEguSJza-PIikw8gvWqrtwTYMJqITI5SW2mEiWSPI2d5EZobhHYWRPA6_5vl6YjQKc8HF_LlrqZl_jZS__ZA3g5iJ61rB9_EtrqVabsDL8pES2lRS4RGgTwYihGkyU_jKpcvSCZmPMIcWAewONWw4ZaBJc4ycuzALIV3RsEiA58taSannpacMo8kIoIX9Or1t8bXh6Mj_3J038X3YTbnFYa_C7MLVifny_cM4Rjc_3c291vE_g2bg
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtQwEB6VIgGXQvkNFDAIJC7ZJnacnwOHqqXa_myFSlv1FhzbKxa6SdXsLmpPPAIvwY1X4SV4EsbOT7ttkbj0wCWK4kns2GPPZ3v8DcArHvmKe9J3ufBxgiIy7SY4jXBlyChD--Zpe0KutxV2d4P1fb4_Az-bszAVP0S74GZ6hh2vTQc3C9KLp6yhn4eTDuL_kNYulRv6-CtO2Mq3ayvYuq8pXX23s9x165gCruQsoq5KAuUJwxkvUNMTnvWZ4JjEpOLmYZAFiuJj7vdlhqZNIOAwW1-xUr6nWMTwu9fguokgbpj6V7ZPyaripNqzwLHHRavHGx4jjy62RZ22fhcg7UXPzLOI2Zq81dvwq6msytPlS2c8yjry5ByP5P9Sm3dgrsbeZKnqLPMwo_O7cKNXexfcgx_vi5FxnkIZhPIE_8j4CRnNJUWffFja_v3t-3Kxh1dK6vhGZCKkbIRESQa58VzQimTH599vXDdRxsaFORFkMjgal7psP2ZZVjH3Q7OyPxzIkmAxhji9OZvNfdi9kkp6ALN5ketHQJjKGIt4P1SRCAQL4tDXnEqWUYXYVUkH3jTqlcqa492EGjlIK3ZqmmIzp7aZHXjZih5WxCaXCS00OprWY1uZIiAMk5gj-nHgRZuMo5LZahK5LsZGxqfUQ6gbO_CwUuk2F0Y5zmPjyIFoStlbAcN4Pp2SDz5Z5nMTXCFkHv6m1eW_Fzxd7-3Zm8f_LvocbnZ3epvp5trWxhO4Rc3Cij10ugCzo6Oxforoc5Q9s52ewMer7hd_AKfXkgo
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtQwFL0qRarY8H4EChgEEptMEzvOY8Gi6jDqg6mqQqvuUsd2xACTGTUzg9oVn8BPsOJX-Aq-hGvn0U4LEpsu2ERRfBM79rXvsX19LsALHvmKe9J3ufBxgiIy7SY4jXBlyChD--Zpe0Kuvx2u7wWbB_xgAX40Z2Eqfoh2wc30DDtemw4-VvnKKWnox-Gsg_A_pLVH5ZY-_oLztfL1Rhcb9yWlvTfv19bdOqSAKzmLqKuSQHnCUMYLVPSEZzkTHJOYVNw8DLJAUXzM_VxmaNkE4g2z8xUr5XuKRQy_ewWuBqGXmDgR3d1Trqo4qbYscOhx0ejxhsbIoyttUeeN3wVEe9Ex8yxgthavdwN-NnVVObp86kwnWUeenKOR_E8q8yZcr5E3Wa26yi1Y0MVtWOrXvgV34PvOaGJcp1AGgTzBHzJeQkZvySgn71Z3f339tjbaxysldXQjMhNSNkKiJIPC-C1oRbLj8-83jpsoY6PCnAgyGxxNS122H7Mcq5j72KzrDweyJFiMIU5uzmZzF_YupZLuwWIxKvQDIExljEU8D1UkAsGCOPQ1p5JlVCFyVdKBV412pbJmeDeBRj6nFTc1TbGZU9vMDjxvRccVrcmfhJYbFU3rka1MEQ6GScwR-zjwrE3GMclsNIlCj6ZGxqfUQ6AbO3C_0ug2F0Y5zmLjyIFoTtdbAcN3Pp9SDD5Y3nMTWiFkHv6mVeW_Fzzd7O_bm4f_LvoUlna6vfTtxvbWI7hGzaqKPXG6DIuTo6l-jNBzkj2xXZ7A4WV3i99eDpC5
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Potential+for+elimination+of+SAR-CoV-2+through+vaccination+as+inspired+by+elimination+of+multiple+influenza+viruses+through+natural+pandemics+or+mass+vaccination&rft.jtitle=Journal+of+medical+virology&rft.au=Chen%2C+Ji-Ming&rft.au=Sun%2C+Ying-Xue&rft.au=Chen%2C+Ji-Wang&rft.date=2020-11-01&rft.eissn=1096-9071&rft.volume=92&rft.issue=11&rft.spage=2453&rft_id=info:doi/10.1002%2Fjmv.26162&rft_id=info%3Apmid%2F32525587&rft.externalDocID=32525587
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0146-6615&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0146-6615&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0146-6615&client=summon